Metasyn joins forces with Daiichi
Contrast developer Metasyn has signed a $12 million agreementwith Daiichi Radioisotope Laboratories of Tokyo for Japanese developmentand marketing of MS-325, Metasyn's vascular MRI contrast agent.Under the agreement, Metasyn will receive $12 million in
Contrast developer Metasyn has signed a $12 million agreement
with Daiichi Radioisotope Laboratories of Tokyo for Japanese development
and marketing of MS-325, Metasyn's vascular MRI contrast agent.
Under the agreement, Metasyn will receive $12 million in license
fees, milestone payments, and an equity investment, in addition
to royalties on sales of the product. Daiichi will be responsible
for clinical development, registration, and commercialization
of MS-325 in Japan. Metasyn, of Cambridge, MA, will manufacture
MS-325 for Daiichi and will retain rights to the product outside
Japan. Metasyn expects to begin clinical trials of the agent in
the U.S. this year.
